Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III)

Neuroepidemiology

Volumn 24, Issue 1-2, 2005, Pages 42-50

  Pavlik, Valory N ^a   Hyman, David J ^a   Doody, Rachelle ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular risk factors; Serial Digit Learning Test; Simple Reaction Time Test; Symbol Digit Substitution Test

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR RISK; COGNITION; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; FUNCTION TEST; GROUPS BY AGE; HEALTH BEHAVIOR; HUMAN; HYPERTENSION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL TASK; RISK ASSESSMENT; SERIAL DIGIT LEARNING TEST; SIMPLE REACTION TIME TEST; SYMBOL DIGIT SUBSTITUTION TEST; TASK PERFORMANCE;

ADULT; ALCOHOL DRINKING; ANTHROPOMETRY; CARDIOVASCULAR DISEASES; COGNITION; DIABETES MELLITUS; EDUCATION; FEMALE; HUMANS; HYPERTENSION; LEARNING; LINEAR MODELS; LIPIDS; MALE; MEMORY, SHORT-TERM; METABOLIC SYNDROME X; MIDDLE AGED; MOTOR ACTIVITY; PSYCHOMOTOR PERFORMANCE; REACTION TIME; RISK FACTORS; SMOKING; SOCIOECONOMIC FACTORS; VISUAL PERCEPTION;

EID: 10844222378     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081049     Document Type: Article

References (57)

1. Hebert LE, Beckett LA, Scherr PA, Evans DA: Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 2001;15:169-173.
2. Cummings JL, Cole G: Alzheimer disease. JAMA 2002;287:2335-2338.
3. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002;297:353-356.
4. Roman GC: Vascular dementia revisited: Diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 2002;86:477-499.
5. Greicius MD, Geschwind MD, Miller BL: Presenile dementia syndromes: An update on taxonomy and diagnosis. J Neurol Neurosurg Psychiatry 2002;72:691-700.
6. Birkenhager WH, Forette F, Seux ML, Wang JG, Staessen JA: Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med 2001;161:152-156.
7. Davis RN, Massman PJ, Doody RS: Effects of blood pressure on neuropsychological functioning in Alzheimer's disease. Arch Clin Neuropsychol 2003;18:19-32.
8. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al: 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-1145.
9. Swan GE, DeCarli C, Miller BL, Reed T, Wolf PA, Jack LM, et al: Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology 1998;51:986-993.
10. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, et al: Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001;56:42-48.
11. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al: Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population-based study. BMJ 2001;322:1447-1451.
12. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al: Midlife blood pressure and dementia: The Honolulu-Asia aging study. Neurobiol Aging 2000;21:49-55.
13. Elias PK, Elias MF, D'Agostino RB, Cupples LA, Wilson PW, Silbershatz H, et al: NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 1997;20:1388-1395.
14. Glynn RJ, Beckett LA, Hebert LE, Morris MC, Scherr PA, Evans DA: Current and remote blood pressure and cognitive decline. JAMA 1999;281:438-445.
15. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R: The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002;58:1175-1181.
16. Kalmijn S, Feskens EJ, Launer LJ, Stijnen T, Kromhout D: Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995;38:1096-1102.
17. Cerhan J, Folsom A, Mortimer J, Shahar E, Knopman D, McGovern P, et al: Correlates of cognitive function in middle-aged adults. Gerontology 1998;44:95-105.
18. Grodstein F, Chen J, Wilson RS, Manson JE: Type 2 diabetes and cognitive function in community-dwelling elderly women. Diabetes Care 2001;24:1060-1065.
19. Gregg EW, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, Narayan KM, et al: Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000;160:174-180.
20. Vanhanen M, Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Hanninen T, et al: Type-2 diabetes and cognitive function in a non-demented population. Acta Neurol Scand 1999;100:97-101.
21. Lindeman RD, Romero LJ, LaRue A, Yau CL, Schade DS, Koehler KM, et al: A biethnic community survey of cognition in participants with type 2 diabetes, impaired glucose tolerance, and normal glucose tolerance: The New Mexico Elder Health Survey. Diabetes Care 2001;24:1567-1572.
22. Isbir T, Agachan B, Yilmaz H, Aydin M, Kara I, Eker E, et al: Apolipoprotein-E gene polymorphism and lipid profiles in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2001;16:77-81.
23. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
24. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al: Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
25. Staehelin HB, Perrig-Chiello P, Mitrache C, Miserez AR, Perrig WJ: Apolipoprotein E genotypes and cognitive functions in healthy elderly persons. Acta Neurol Scand 1999;100:53-60.
26. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al: Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
27. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, et al: Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology 2001;56:1683-1689.
28. Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, et al: Plasma total cholesterol level as a risk factor for Alzheimer disease: The Framingham Study. Arch Intern Med 2003;163:1053-1057.
29. Romas SN, Tang MX, Berglund L, Mayeux R: APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 1999;53:517-521.
30. Jagust W: Untangling vascular dementia. Lancet 2001;358:2097-2098.
31. de la Torre JC: Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 2002;33:1152-1162.
32. de la Torre JC, Stefano GB: Evidence that Alzheimer's disease is a microvascular disorder: The role of constitutive nitric oxide. Brain Res Rev 2000;34:119-136.
33. National Center for Health Statistics: Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Hyattsville, MD: National Center for Health Statistics, 1994. Report No. Vital Health Stat 1. http://www.cdc.gov/scientific.htm.
34. Letz R: Use of computerized test batteries for quantifying neurobehavioral outcomes. Environ Health Perspect 1991;90:195-198.
35. Baker E, Letz R, Fidler A: A computer-administered neurobehavioral evaluation system for occupational and environmental epidemiology. Rationale, methodology, and pilot study results. J Occup Med 1985;27:206-212.
36. Wechsler D: WAIS-R Manual. Cleveland, The Psychologic Corporation, 1981.
37. Krieger N, Williams DR, Moss NE: Measuring social class in US public health research: Concepts, methodologies, and guidelines. Annu Rev Public Health 1997;18:341-378.
38. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
39. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, et al: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Hypertension 1995;26:60-69.
40. American Diabetes Association: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-1197.
41. Crespo C, Keteyian S, Heath G, Sempos C: Leisure-time physical activity among US adults. Arch Intern Med 1996;1996:93-98.
42. Shah B, Barnwell B, Bieler G: SUDAAN User's Manual, Release 7.5. Research Triangle Park, Research Triangle Institute, 1997.
43. Kaufman AS, McLean JE, Reynolds CR: Sex, race, residence, region, and education differences on the 11 WAIS- R subtests. J Clin Psychol 1988;44:231-248.
44. Kramer RA, Allen L, Gergen PJ: Health and social characteristics and children's cognitive functioning: Results from a national cohort. Am J Public Health 1995;85:312-318.
45. Letz R, Pieper WA, Morris RD: NES test performance in a large US Army veteran sample: Relationships with both demographic factors and traditional neuropsychological measures. Neurotoxicol Teratol 1996;18:381-390.
46. Loewenstein DA, Arguelles T, Arguelles S, Linn-Fuentes P: Potential cultural bias in the neuropsychological assessment of the older adult. J Clin Exp Neuropsychol 1994;16:623-629.
47. Leroi I, Sheppard JM, Lyketsos CG: Cognitive function after 11.5 years of alcohol use: Relation to alcohol use. Am J Epidemiol 2002;156:747-752.
48. Vliegenthart R, Geleijnse JM, Hofman A, Meijer WT, van Rooij FJ, Grobbee DE, et al: Alcohol consumption and risk of peripheral arterial disease: The Rotterdam study. Am J Epidemiol 2002;155:332-338.
49. de Lorgeril M, Salen P, Martin JL, Boucher F, Paillard F, de Leiris J: Wine drinking and risks of cardiovascular complications after recent acute myocardial infarction. Circulation 2002;106:1465-1469.
50. Kalmijn S, van Boxtel MP, Verschuren MW, Jolles J, Launer LJ: Cigarette smoking and alcohol consumption in relation to cognitive performance in middle age. Am J Epidemiol 2002;156:936-944.
51. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
52. Liese AD, Mayer-Davis EJ, Haffner SM: Development of the multiple metabolic syndrome: An epidemiologic perspective. Epidemiol Rev 1998;20:157-172.
53. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
54. Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H, et al: Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 2000;20:2255-2260.
55. Hanley AJ, Karter AJ, Festa A, D'Agostino R Jr, Wagenknecht LE, Savage P, et al: Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. Diabetes 2002;51:2642-2647.
56. Hanson RL, Imperatore G, Bennett PH, Knowler WC: Components of the 'metabolic syndrome' and incidence of type 2 diabetes. Diabetes 2002;51:3120-3127.
57. Anderson PJ, Critchley JA, Chan JC, Cockram CS, Lee ZS, Thomas GN, et al: Factor analysis of the metabolic syndrome: Obesity vs insulin resistance as the central abnormality. Int J Obes Relat Metab Disord 2001;25:1782-1788.